CIM
CYTK icon

Contravisory Investment Management’s Cytokinetics CYTK Stock Holding History

Contravisory Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-143
Closed -$5.03K – 314
2023
Q1 		$5.03K Hold
143
– – ﹤0.01% 308
2022
Q4 		$6.55K Hold
143
– – ﹤0.01% 267
2022
Q3 		$7K Hold
143
– – ﹤0.01% 262
2022
Q2 		$6K Hold
143
– – ﹤0.01% 264
2022
Q1 		$5K Buy
+143
New +$5.08K ﹤0.01% 293

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Contravisory Investment Management's CYTK Position: Q2 2023 in Review

Contravisory Investment Management sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 143 shares — an estimated $5.03K sold.

Contravisory Investment Management first reported a position in CYTK in Q1 2022 and held it in 5 quarters. The position peaked at $7K in Q3 2022. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

  • Contravisory Investment Management reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
  • Contravisory Investment Management sold 143 Cytokinetics shares in Q2 2023, an estimated $5.03K.
  • Contravisory Investment Management first reported a position in Cytokinetics in Q1 2022 and held it in 5 quarters.
  • Contravisory Investment Management's Cytokinetics position peaked at $7K in Q3 2022.
  • 253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Contravisory Investment Management's 13F filing for Q2 2023, filed 12 Jul 2023.